Journal of Microbiology

The Microbiological Society of Korea (한국미생물학회)
권호 표지

A Recombinant Human ${\alpha}_1$-Antitrypsin Variant, $M_{malton}$, Undergoes a Spontaneous Conformational Conversion into a Latent Form

  • Jung, Chan-Hun (Department of Molecular Biology, Sejong University) ;
  • Im, Hana (Department of Molecular Biology, Sejong University)
  • Published : 2003.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Many genetic variants of ${\alpha}_1$-antitrypsin have been associated with early onset emphysema and liver cirrhosis. However, the detailed structural basis of pathogenic ${\alpha}_1$-antitrypsin molecules is rarely known. Here we found that a recombinant $M_{malton}$ variant (Phe52-deleted) lost inhibitory activity by spontaneous conformational conversion into a more stable, inactive form under physiological conditions. Biochemical and spectroscopic data suggested that the variant converts into a reactive center loop-inserted conformation, resembling the latent form of plasminogen activator inhibitor-1.

Keywords

References

  1. Aertgeerts, K., H.L. De Bondt, C.J. De Ranter, and P.J. Declerck. 1995. Mechanism contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 2, 891-897.
  2. Bruce, D., D. Perry, J.Y. Borg, R.W. Carrell, and M.R. Wardell. 1994. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn->Asp). J. Clin. Invest. 94, 2265-2274.
  3. Bruch, M., V. Weiss, and J. Engel. 1988. Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263, 16626-16630.
  4. Carrell, R.W., J.-O. Jeppsson, C.-B. Laurell, S.O. Brennan, M.C. Owen, L. Vaughan, and D.R. Boswell. 1982. Structure and variation of human $\alpha_{1}$-antitrypsin. Nature 298, 329-334.
  5. Carrell, R.W., D.L. Evans, and P.E. Stein. 1991. Mobile reactive centre of serpins and the control of thrombosis. Nature 353, 576-578.
  6. Elliott, P.R., D.A. Lomas, R.W. Carrell, and J.-P. Abrahams. 1996. Inhibitory conformation of the reactive loop of $\alpha$1-antitrypsin. Nat. Struct. Biol. 3, 676-681.
  7. Eriksson, S., J. Carlson, and R. Velez. 1986. Risk of cirrhosis and primary liver cancer in $\alpha$1-antitrypsin deficiency. New Engl. J. Med. 314, 736-739.
  8. Gils, A., I. Knockaert, and P.J. Declerck. 1996. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 35, 7474-7481.
  9. Goldenberg, D.P. 1989. Analysis of protein conformation by gel electrophoresis, p. 225-250. In T.E. Creighton (ed.), Protein Structure: A Practical Approach. IRL Press at Oxford University Press, Oxford, UK.
  10. Gooptu, B., B. Hazes, W.S. Chang, T.R. Dafform, R.W. Carrell, R.J. Read, and D.A. Lomas. 2000. Inactive conformation of the serpin $\alpha$1-antichymotrypsin indicates two-stage insertion of the reactive loop: Implications for inhibitory function and conformational disease. Proc. Natl. Acad. Sci. USA. 97, 67-72.
  11. Hekman, C.M. and D.J. Loskutoff. 1985. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260, 11581-11587.
  12. Hopkins, P.C.R., R.W. Carrell, and S.R. Stone. 1993. Effects of mutations in the hinge region of serpins. Biochemistry 32, 7650-7657.
  13. Huber, R. and R.W. Carrell. 1989. Implications of the three-dimensional structure of $\alpha$1-antitrypsin for structure and function of serpins. Biochemistry 28, 8951-8966
  14. Huntington, J.A., B. Fan, K.E. Karlsson, J. Deinum, D.A. Lawrence, and P.G.W. Gettins. 1997. Serpin conformational change in ovalbumin: Enhanced reactive center loop insertion through hinge region mutations. Biochemistry 36, 5432-5440.
  15. Im, H., M.-S. Woo, K.Y. Hwang, and M.-H. Yu. 2002. Interactions causing the kinetic trap in serpin protein folding. J. Biol. Chem. 277, 46347-46354.
  16. Johnson, D. and J. Travis. 1978. Structural evidence for methionine at the reactive site of human $\alpha$1-proteinase inhibitor. J. Biol. Chem. 253, 7142-7144
  17. Kwon, K.-S., J. Kim, H.S. Shin, and M.-H. Yu. 1994. Single amino acid substitutions of $\alpha$1-antitrypsin that confer enhancement in thermal stability. J. Biol. Chem. 269, 9627-9631
  18. Lawrence, D., L. Strandberg, T. Grundstrom, and T. Ny. 1989. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur. J. Biochem. 186, 523-533.
  19. Loebermann, H., R. Tokuoka, J. Deisenhofer, and R. Huber. 1984. Human $\alpha$1-antitrypsin: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177, 531-556
  20. Lomas, D.A., P.R. Elliott, W.-S. Chang, M.R. Wardell, and R.W. Carrell. 1995a. Preparation and characterization of latent alpha 1-antitrypsin. J. Biol. Chem. 270, 5282-5288 https://doi.org/10.1074/jbc.270.10.5282
  21. Lomas, D.A., P.R. Elliott, S.K. Sidhar, R.C. Foreman, J.T. Finch, D.W. Cox, J.C. Whisstock, and R.W. Carrell. 1995b. $\alpha$1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo: Evidence for the C sheet mechanism of polymerization. J. Biol. Chem. 270, 16864-16870
  22. Lukacs, C.M., J.Q. Zhong, M.I. Plotnick, H. Rubin, B.S. Cooperman, and D.W. Christianson. 1996. Arginine substitutions in the hinge region of antichymotrypsin affect serpin beta-sheet rearrangement. Nat. Struct. Biol. 3, 888-893.
  23. Mast, A.E., J.J. Enghild, and G. Salvesen. 1992. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry 31, 2720-2728.
  24. Mottonen, J., A. Strand, J. Symersky, R.M. Sweet, D.E. Danley, K.F. Geoghegan, R.D. Gerard, and E.J. Goldsmith. 1992. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355, 270-273.
  25. Owen, M.C., S.O. Brennan, J.H. Lewis, and R.W. Carrell. 1983. Mutation of antitrypsin to antithrombin: $\alpha$1-Antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. New Engl. J. Med. 309, 694-698
  26. Ryu, S.-E., H.-J. Choi, K.-S. Kwon, K. Lee, and M.-H. Yu. 1996. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: Crystal structure of an uncleaved $\alpha$1-antitrypsin at 2.7A. Structure 4, 1181-1192
  27. Stein, P.E. and R.W. Carrell. 1995. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2, 96-113.
  28. Wang, Z., J. Mottonen, and E.J. Goldsmith. 1996. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1. Biochemistry 35, 16443-16448.
  29. Wright, H.T. and J.N. Scarsdale. 1995. Structural basis for serpin inhibitor activity. Proteins. 22, 210-225.
  30. Yu, M.-H., K.N. Lee, and J. Kim. 1995. The Z type variation of human $\alpha$1-antitrypsin causes a protein folding defect. Nat. Struct. Biol. 2, 363-367